Zogenix Inc logo

ZGNX - Zogenix Inc Share Price

$30.16 0.6  2.0%

Last Trade - 02/06/20

Sector
Healthcare
Size
Mid Cap
Market Cap £1.31bn
Enterprise Value £973.2m
Revenue £3.92m
Position in Universe 1885th / 6317
Bullish
Bearish
Unlock ZGNX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Zogenix, Inc. revenues increased from $0K to $1.2M. Net loss decreased 27% to $25.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income (expense) increase from $88K (expense) to $20M (income), Fair Value Adjustments on Other Assets decrease from $3M (expense) to $7.9M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZGNX Revenue Unlock ZGNX Revenue

Net Income

ZGNX Net Income Unlock ZGNX Revenue

Normalised EPS

ZGNX Normalised EPS Unlock ZGNX Revenue

PE Ratio Range

ZGNX PE Ratio Range Unlock ZGNX Revenue

Dividend Yield Range

ZGNX Dividend Yield Range Unlock ZGNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZGNX EPS Forecasts Unlock ZGNX Revenue
Profile Summary

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated May 11, 2006
Public Since November 23, 2010
No. of Shareholders: 9
No. of Employees: 141
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 55,340,691
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZGNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZGNX
Upcoming Events for ZGNX
Thursday 6th August, 2020 Estimate
Q2 2020 Zogenix Inc Earnings Release
Friday 6th November, 2020 Estimate
Q3 2020 Zogenix Inc Earnings Release
Frequently Asked Questions for Zogenix Inc
What is the Zogenix Inc share price?

As of 02/06/20, shares in Zogenix Inc are trading at $30.16, giving the company a market capitalisation of £1.31bn. This share price information is delayed by 15 minutes.

How has the Zogenix Inc share price performed this year?

Shares in Zogenix Inc are currently trading at $30.16 and the price has moved by -21.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zogenix Inc price has moved by -29.3% over the past year.

What are the analyst and broker recommendations for Zogenix Inc?

Of the analysts with advisory recommendations for Zogenix Inc, there are there are currently 5 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zogenix Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zogenix Inc next release its financial results?

Zogenix Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Zogenix Inc dividend yield?

Zogenix Inc does not currently pay a dividend.

Does Zogenix Inc pay a dividend?

Zogenix Inc does not currently pay a dividend.

When does Zogenix Inc next pay dividends?

Zogenix Inc does not currently pay a dividend.

How do I buy Zogenix Inc shares?

To buy shares in Zogenix Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zogenix Inc?

Shares in Zogenix Inc are currently trading at $30.16, giving the company a market capitalisation of £1.31bn.

Where are Zogenix Inc shares listed? Where are Zogenix Inc shares listed?

Here are the trading details for Zogenix Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: ZGNX
What kind of share is Zogenix Inc?

Based on an overall assessment of its quality, value and momentum, Zogenix Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zogenix Inc share price forecast 2020?

Shares in Zogenix Inc are currently priced at $30.16. At that level they are trading at 73.14% discount to the analyst consensus target price of 0.00.

Analysts covering Zogenix Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.266 for the next financial year.

How can I tell whether the Zogenix Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zogenix Inc. Over the past six months, the relative strength of its shares against the market has been -35.31%. At the current price of $30.16, shares in Zogenix Inc are trading at -23.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zogenix Inc PE Ratio?

We were not able to find PE ratio data for Zogenix Inc.

Who are the key directors of Zogenix Inc?

Zogenix Inc's management team is headed by:

Stephen Farr - PRE
Michael Smith - CFO
Cam Garner - CHM
Bradley Galer - EVP
Louis Bock - IND
Renee Tannenbaum - IND
Gail Farfel - EVP
Ashish Sagrolikar - EVP
Erle Mast - IND
Mark Wiggins - IND
James Breitmeyer - IND
Shawnte Mitchell - EVP
Who are the major shareholders of Zogenix Inc?

Here are the top five shareholders of Zogenix Inc based on the size of their shareholding:

RA Capital Management, LP Hedge Fund
Percentage owned: 9.53% (5.28m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.12% (3.94m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 6.24% (3.45m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.8% (3.21m shares)
Eventide Asset Management, LLC Investment Advisor
Percentage owned: 5.13% (2.84m shares)
Similar to ZGNX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.